AI Article Synopsis

  • A 48-year-old man with a history of pulmonary and ocular sarcoidosis was diagnosed with hepatic sarcoidosis after biopsies showed non-caseating granulomas in the liver.
  • Diagnostic imaging revealed lymphadenopathy and liver infiltration, leading to treatment with ursodeoxycholic acid and later prednisone.
  • After five years on a low dose of prednisone, the patient showed significant improvement, with follow-up biopsies indicating minimal inflammation and stable fibrosis levels.

Article Abstract

We report the case of a 48-year-old male with a history of pulmonary and ocular sarcoidosis. Non-caseating granulomas, identified histologically, are the most characteristic manifestation of sarcoidosis. Hepatic sarcoidosis is difficult to diagnose using radiological imaging. In the patient reported in this study, ultrasound and contrast-enhanced computed tomography scans identified multiple intra-abdominal lymphadenopathies, with evidence of liver and splenic infiltrations. The first liver biopsy revealed non-caseating granulomatous hepatitis consistent with hepatic sarcoidosis. The patient was treated with ursodeoxycholic acid (UDCA), but his laboratory parameters did not improve. Prednisone was initiated at a dose of 30 mg daily and slowly tapered. At a dose of 12.5 mg daily, marked improvements in the fibrotic and sarcoid-like lesions were noted at the second biopsy. A third biopsy was performed, with the patient on a prednisone taper of 5 mg/day showed mild fibrous expansion in the portal tracts and mild parenchymal necro-inflammatory lesions. However, overall, fibrosis marker levels remained stable over the course of treatment. A fourth biopsy was performed after a 5-year course of 5 mg/day prednisone. This revealed minimal lobular inflammation without fibrosis. Thus, treatment of this patient with corticosteroids and UDCA resulted in marked improvements in his biochemical and histological parameters.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12328-023-01918-3DOI Listing

Publication Analysis

Top Keywords

hepatic sarcoidosis
12
ursodeoxycholic acid
8
marked improvements
8
biopsy performed
8
sarcoidosis
5
improvement liver
4
liver histology
4
histology hepatic
4
sarcoidosis treatment
4
treatment corticosteroids
4

Similar Publications

Multisystemic Sarcoidosis in the Primary Care Setting: A Case Report.

Cureus

December 2024

Family Medicine, Unidade de Saúde Familiar (USF) Amato Lusitano, Unidade Local de Saúde (ULS) de Amadora/Sintra, Amadora, PRT.

Sarcoidosis is a rare, multisystemic disease of unknown etiology, characterized by noncaseating granulomas in various organs. The disease often presents with nonspecific symptoms that complicate the diagnosis. We describe the case of a 31-year-old woman who presented to her family doctor with weight loss, cervical lymphadenopathy, parotid edema, and cutaneous lesions, initially raising suspicion of a lymphoproliferative disorder.

View Article and Find Full Text PDF

Erythema induratum of Bazin (EIB) is a rare manifestation of cutaneous tuberculosis, typically associated with active tuberculosis infections. We present the case of a 75-year-old immunocompetent Spanish woman who developed nodular lesions on her lower limbs. Initial differential diagnoses included sporotrichosis, erythema nodosum, Sweet's syndrome, sarcoidosis, and tuberculosis.

View Article and Find Full Text PDF

Hepatic sarcoidosis is rare, and its similarity to liver metastases complicates the diagnosis. This mimicry requires a thorough diagnostic investigations to exclude neoplasia and other granulomatous diseases, particularly tuberculosis. A 36-year-old male presented with a two-month history of right hypochondrial tenderness, anorexia, asthenia, and weight loss.

View Article and Find Full Text PDF

Aim Of The Study: Sarcoidosis is characterized by noncaseating granulomas that can affect multiple organs. Due to the lack of prospective studies regarding treatment of hepatic sarcoidosis with ursodeoxycholic acid (UDCA), we set out to evaluate its effects in a single-center, open-label, prospective, pre-post study.

Material And Methods: A total of 10 patients were screened from August 2018 to July 2020; seven met the criteria and were enrolled.

View Article and Find Full Text PDF

: Anti PD1/PD-L1 agents, including pembrolizumab, have revolutionized the oncological treatment of different types of cancer, including non-small cell lung cancer. The most frequent complications associated with this type of treatment are mild and are located at the thyroid, pulmonary or hepatic level. Sarcoid like reaction and mesenteric panniculitis secondary to pembrolizumab treatment are two very rare adverse effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!